Pharma-Bio Serv (PBSV) Stock Analysis & Winston Score

Pharma-Bio Serv is a consulting and compliance services company that helps businesses in the pharmaceutical, biotechnology, food, and medical device industries follow government regulations. Its main services include training, audits, quality assurance support, and regulatory consulting. The company primarily serves manufacturers and producers who need to meet strict safety and quality standards set by agencies like the FDA.

The company earns revenue by charging fees for its consulting projects and training programs rather than selling physical products. It operates mainly in Puerto Rico and the broader United States, serving a region with a significant concentration of pharmaceutical manufacturing facilities. Pharma-Bio Serv is a small company with a market cap near zero, and it faces real financial pressure, as its negative operating margin shows it is currently spending more than it earns. The key risk is its small size and limited resources, which make it vulnerable to losing clients to larger, better-funded consulting firms.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-7.1% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-99.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

64.9%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~4 years

$5.8B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$5.8B cash & investments at current burn rate

Revenue declining

Pharma-Bio Serv's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.3% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 23.0M (2021) → 23.0M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

31.5%

Modest — 31.5% gross margin

Operating Margin

-4.1%

Losing money on operations — -4.1%

ROCE

-0.0%

Weak — -0.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+20419.3%

Fast-growing sales (20419.3% YoY)

EPS YoY

-197.8%

Earnings shrinking (-197.8% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-7.8%

Burning cash (-7.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

13.16%

Healthy income — 13.16% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend Growth

+0.0%

Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial